Mizuho Lowers Assembly Biosciences (NASDAQ:ASMB) Price Target to $3.00

Assembly Biosciences (NASDAQ:ASMBGet Rating) had its target price cut by investment analysts at Mizuho from $14.00 to $3.00 in a report released on Wednesday, The Fly reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s target price would suggest a potential upside of 117.39% from the stock’s previous close.

Several other research firms also recently commented on ASMB. StockNews.com began coverage on Assembly Biosciences in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. HC Wainwright cut their target price on Assembly Biosciences from $3.50 to $2.50 in a research report on Thursday, July 21st. Finally, Truist Financial cut Assembly Biosciences from a “buy” rating to a “hold” rating and cut their target price for the stock from $11.00 to $2.00 in a research report on Monday, October 24th.

Assembly Biosciences Stock Up 4.5 %

NASDAQ ASMB opened at $1.38 on Wednesday. The stock’s 50-day moving average price is $1.66 and its 200-day moving average price is $1.86. Assembly Biosciences has a 52 week low of $1.20 and a 52 week high of $2.51. The company has a market capitalization of $67.32 million, a P/E ratio of -0.49 and a beta of 0.72.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new position in Assembly Biosciences during the 1st quarter valued at approximately $27,000. Tower Research Capital LLC TRC grew its holdings in Assembly Biosciences by 110.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 17,150 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 8,992 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Assembly Biosciences by 15,633.0% during the 1st quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 14,695 shares in the last quarter. Prudential Financial Inc. purchased a new position in Assembly Biosciences during the 2nd quarter valued at approximately $36,000. Finally, Virtu Financial LLC purchased a new position in Assembly Biosciences during the 3rd quarter valued at approximately $49,000. Hedge funds and other institutional investors own 35.49% of the company’s stock.

Assembly Biosciences Company Profile

(Get Rating)

Assembly Biosciences, Inc, a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.

See Also

The Fly logo

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.